North America to Dominate Haemophilia Treatment Market During Forecast Period
Increasing number of haemophilic
patients worldwide and increased diagnosis rate across the globe to drive
global haemophilia treatment market
According
to TechSci Research report, “Global Haemophilia
Treatment Market By Type, By Product, By Treatment, By Therapy, By Region,
Competition, Forecast & Opportunities, 2025”, global
haemophilia treatment market is expected to witness significant CAGR during the
forecast period. Increasing number of haemophilic patients worldwide is one of the major factors accounting
for the growth of global haemophilia treatment market.
Moreover, upsurge in the use of prophylactic treatment for hemophilia is
expected to bode well for the growth of global haemophilia treatment market
through the forecast period. In addition to this, supportive initiatives plan
by governments worldwide in order to commence early screening of neonates is
expected to positively influence the growth of global haemophilia treatment
market in the years to come. Also, growing severity with the genetic evolution,
is making headway for the growth of global haemophilia treatment market. Furthermore,
rising availability of hemophilia drugs is also contributing to increasing
market growth. However, there are certain factors that might hamper the growth
of global haemophilia treatment market over the coming years including high
cost of recombinant products, stringent government regulations and serious
adverse effects associated with plasma derived products.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on " Global Haemophilia
Treatment Market "
https://www.techsciresearch.com/report/haemophilia-treatment-market/5057.html
Global
haemophilia treatment market can be segmented based on type, product,
treatment, therapy, company, and region. Considering the product, the market is
fragmented into plasma derived coagulation factor concentrate, recombinant
coagulation factor concentrates, desmopressin, and antifibrinolytics agents. Here,
the recombinant coagulation factor concentrates segment dominated the global haemophilia
treatment market in terms of largest market share until 2019 and is further
anticipated to maintain its dominance during the forecast period as well, which
can be accredited to increase in production of recombinant factor concentrates
to treat hemophilia coupled with high availability of plasma-derived
concentrates. Moreover, enhanced safety of replacement therapy by using
recombinant factor concentrates, is further boosting the segmental growth. In
terms of treatment, the market is categorized into on-demand and prophylaxis.
Out of which, the prophylaxis treatment segment is forecast to grow at a high
CAGR in the years to come, on account of its efficiency and better end results.
Additionally, preference for long-term prophylaxis treatment to prevent chronic
arthropathy and joint bleeding in patients with severe haemophilia, is further contributing
to the growth of the segment.
Novo
Nordisk A/S, Shire, Chugai Pharmaceutical Co. Ltd., Bayer AG, Pfizer, Inc., CSL
Behring, BioMarin, Octopharma AG, Genzyme Corporation, Spark Therapeutics,
Inc., Baxter International, Inc.s, Grifols SA, Kedrion, Biogen Idec, Inc.,
Hospira, Incare among others are the leading players operating in global haemophilia
treatment market. The players are adopting several growth strategies to enhance
the market scenario of haemophilia treatment. Other competitive strategies
include mergers & acquisitions; agreements, partnerships, and
collaborations; and expansions to diverse their product portfolio in order to
strengthen their market position.
download
sample report @ https://www.techsciresearch.com/sample-report.aspx?cid=5057
customers can also request for 10% free
customization on this report.
“North America is forecast to dominate the global haemophilia treatment market
during the next five years on account of presence of favorable healthcare reimbursement
and insurance policies in the region. Furthermore, growing demand and adoption
rate of haemophilia medications is also contributing to the growing trend. Additionally,
better diagnostic techniques in the region is anticipated to bolster the growth
of growth of global haemophilia treatment market over the coming years.”, said
Mr. Karan Chechi, Research Director with TechSci Research, a research based
global management consulting firm.
“Global Haemophilia Treatment Market By Type, By
Product, By Treatment, By Therapy, By Region, Competition, Forecast &
Opportunities, 2025” has
evaluated the future growth potential of global haemophilia treatment market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in global haemophilia treatment market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]